Logo image
Back
Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity
Journal article   Open access   Peer reviewed

Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity

Robin A. Laskey, Scott D. Richard, Ashlee L. Smith, Jeff F. Lin, Tiffany L. Beck, Jamie L. Lesnock, Joseph L. Kelley, Alexander B. Olawaiye, Paniti Sukumvanich and Thomas C. Krivak
OncoTargets and therapy, v 7, pp 469-476
01 Jan 2014
DOI: https://doi.org/10.2147/OTT.S57425
PMID: 24711703
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.2147/ott.s57425View
Published, Version of Record (VoR)CC BY-NC V4.0,  Open
url
https://doi.org/10.2147/OTT.S57425View
Published, Version of Record (VoR) Open

Abstract

Biotechnology & Applied Microbiology Life Sciences & Biomedicine Oncology Science & Technology
Purpose: Bevacizumab (Bev) is associated with improved progression-free survival in advanced epithelial ovarian cancer. The use of Bev in patients with gynecologic malignancy is increasing; however, little is known about cumulative toxicity and response in patients retreated with Bev. Our goal was to determine cumulative side effects and response in patients retreated with Bev. Patients and methods: Women with recurrent gynecologic malignancy treated with Bev between January 2007 and March 2012 at a single institution were identified, including a subset who received Bev in a subsequent regimen. The primary outcome was Bev-associated toxicity, and the secondary outcome was response. Results: Of 83 patients that received Bev for recurrent disease, 23 were retreated with Bev and four received Bev maintenance. Three patients (13%) developed grade 3 or 4 hypertension; all had a history of chronic hypertension. One (4.3%) patient developed grade 3 proteinuria, and one (4.3%) developed an enterovaginal fistula. Four patients discontinued Bev secondary to toxicity. Toxicity was not related to the cumulative number of cycles. Twenty-six percent of patients responded to Bev retreatment. On univariate analysis, there was a significant (P=0.003) overall survival advantage when the Bev-free interval was >9 months (95% confidence interval [CI] 4.9-43.7) compared to <= 9 months (95% CI 2.1-11.5), 24.3 months, and 6.8 months. Conclusion: Retreatment of patients with recurrent gynecologic malignancy with Bev did not increase morbidity and was associated with treatment response. Physicians treating women with recurrent disease may consider a Bev-containing regimen even if prior regimen(s) included Bev. Future studies should prospectively evaluate the efficacy of this treatment strategy.

Metrics

4 Record Views
4 citations in Web of Science
4 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#5 Gender Equality
#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Biotechnology & Applied Microbiology
Oncology
Logo image